The 5 drugs tracked here made $14.0B of Amgen’s 2025 revenue (38%) and lose US exclusivity by 2029. Since 2023, Amgen has closed 1 acquisition of $1B or more, worth $27.8B. Products from that deal brought in $3.90B in 2025.
Bars are each drug's 2025 sales as a share of Amgen’s total revenue ($36.8B). Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Oct 2023 | Horizon TherapeuticsAmgen, October 2023 | $27.8B | Other | Rare-disease drugs Tepezza (thyroid eye disease), Krystexxa (gout) and UpliznaAnnounced in December 2022.2025 sales: Tepezza $1.90B, Krystexxa $1.34B, Uplizna $655M Amgen FY2025 | Approved product |
| 1 counted | $27.8B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price Amgen announced, excluding milestone payments unless noted. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Other | $4.4B | $27.8B |
| Immunology | $4.5B | – |
| Cardiometabolic | $3.0B | – |
| Oncology | $2.1B | – |
Amgen has the most revenue at risk in immunology, but has spent the most on acquisitions outside the main areas (Horizon Therapeutics). At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Amgen paid, not the sales it will bring in. Only one of the 1 companies it bought was already selling an approved product at closing (Horizon Therapeutics); the rest brought pipeline drugs whose sales are years away and may never arrive. The closest like-for-like figure is sales of the products Amgen bought: $3.90B in 2025, against $14.0B of 2025 sales losing US exclusivity by 2037. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Revenue: Amgen FY2025. Drug sales and dates are sourced on each drug's page; each deal links to Amgen’s announcement or filing in the table above.
See all 45 drugs on the patent cliff →